drugset

drugset / Trial / NCT05067634

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

NCT05067634 ↗

Phase 3 Active not recruiting 140 enrolled SK Life Science, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures

Timeline

Start: 2022-01-14
Primary completion: 2026-11
Completion: 2026-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cenobamate	Small molecule	12.5 mg	Oral

Indications